Welcome to the December 2018 edition of our Updates for the Advanced Practitioner in Oncology: Side-Effect Management for Hematologic Malignancies newsletter. This month, we highlight the latest news from the 2018 American Society of Hematology Annual Meeting, including new data on ruxolitinib’s role in treating steroid-refractory acute graft-versus-host disease, the effect of ibrutinib dose reduction on progression-free survival in patients with Waldenstrom macroglobulinemia, and the immune-mediated toxicities associated with nivolumab/ipilimumab combination therapy in patients with myelodysplastic syndrome.
We also explore two new FDA drug approvals in acute myeloid leukemia (AML) for patients—glasdegib and venetoclax—and a warning from the FDA about potentially serious side effects of enasidenib for patients with AML. Additionally, we spotlight articles on treating hemolytic anemia associated with rasburicase and employing dose-escalation of ruxolitinib to combat adverse events in patients with myelofibrosis.
If you haven’t yet, make sure to watch our latest roundtable discussion, “Management of Adverse Events of Therapy in Hematologic Malignancies: A Case-Based Series and Overview,” during which three expert colleagues and I review important issues and perspectives in managing side effects for hematologic malignancies.
As always, I hope all of these resources equip you with practical strategies for managing the various adverse effects of therapy for hematologic malignancies. Feel free to share this valuable resource with your colleagues. You can also contact me with comments or suggestions at any time through the JADPRO editors at firstname.lastname@example.org.
Allyson Price, MPAS, PA-C
Physician Assistant, Department of Leukemia
University of Texas MD Anderson Cancer Center